Panacea Biotec Ltd

Panacea Biotec has a strong liquidity position, with cash and equivalents amounting to ₹923.1 million, representing 74.5% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by a current ratio of 1.57 and a low debt-to-equity ratio of 0.02. This indicates a strong ability to meet short-term obligations without reliance on external financing.

The company's profitability metrics are weak, with a net loss of ₹16.63 million and an operating loss of ₹121.08 million in the latest reporting period. Return on equity (ROE) is negative at -0.2%, and return on assets (ROA) is also negative at -0.13%. These figures are below the industry median for profitability metrics, indicating underperformance relative to peers.

Panacea Biotec's revenue is concentrated in a single business segment focused on vaccines and biologics, with no disclosed geographic diversification beyond India. This concentration increases exposure to regulatory and market risks in the domestic pharmaceutical sector.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest period and a significant capital expenditure of ₹828.76 million. While the company is investing in its operations, the lack of positive revenue growth and ongoing operating losses suggest challenges in scaling profitability.

Risk factors include the company's ongoing net losses and operating losses, which could impact its ability to sustain operations without additional financing. However, the low dilution risk and strong liquidity position mitigate some of these concerns. No immediate dilution pressure is expected, and the company has not disclosed any recent equity issuance or shelf registration.

Recent filings and transcripts do not indicate any material events or strategic shifts. The company continues to focus on its core vaccine and biologics business, with no disclosed new product launches or major partnerships in the latest reporting period.

The company maintains a low debt-to-equity ratio of 0.02, significantly below the pharmaceutical cohort median of 0.18.

Free cash flow improved by 80.0% year-over-year, indicating a potential stabilization in cash generation capabilities.

Net income improved by 94.3% year-over-year, suggesting a recovery trajectory from previous significant losses.

Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for investors.

Revenue declined at a 4.1% CAGR over four years, signaling a persistent contraction in top-line growth.

The company faces high credit risk, which could impair its ability to secure favorable financing terms.

Cash conversion ratio of -2.09 places the company in the bottom quartile of its pharmaceutical peers.

Revenue INR 5.59B, +21,6% YoY; Operating income −137,3% YoY.

• ▍Revenue INR 5.59B, +21,6% YoY
• ▍Operating income −137,3% YoY
• ▍Net income +96,5% YoY
• ▍Free cash flow −34,0% YoY
• ▍Net margin -0.2%

Revenue INR 4.60B, −30,4% YoY; Operating income −100,3% YoY.

• ▍Revenue INR 4.60B, −30,4% YoY
• ▍Operating income −100,3% YoY
• ▍Net income −103,1% YoY
• ▍Free cash flow −103,2% YoY
• ▍Net margin -7.2%

Revenue INR 6.61B, +5,8% YoY; Operating income +4 475,6% YoY.

• ▍Revenue INR 6.61B, +5,8% YoY
• ▍Operating income +4 475,6% YoY
• ▍Net income +829,8% YoY
• ▍Free cash flow +1 006,3% YoY
• ▍Net margin 163.0%